Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07302464

Enrollment

Registered

2025-12-24

Start date

2024-10-01

Completion date

2025-06-01

Last updated

2025-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Diabetes, Estimated Glomerular Filtration Rate, Sodium Glucose Co-Transporter 2 Inhibitors

Brief summary

The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.

Detailed description

Glucose reabsorption is mediated by the sodium-glucose cotransporter (SGLT) 2, which reabsorbs 90% of glucose, and SGLT1, which reabsorbs the remaining 10%. The relationship between hyperglycaemia and the development of renal disease is complex. Hyperglycaemia-induced complications are mediated by several metabolic pathways, among which accumulation of Advanced Glycation End-products with abnormalities of the glycosylation of macromolecules and increased glucose flux through the polyol pathway seem to be the most important.

Interventions

OTHERSodium Glucose Co-Transporter 2 Inhibitors

All candidates start therapy with sodium glucose co-transporter 2 (SGLT2) inhibitors with a dose of 10mg daily Dapagliflozin for 6 months

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years. * Both sexes. * Chronic kidney disease (CKD) participants with stages 3 and 4.

Exclusion criteria

* Patients with type 1 diabetes mellitus (DM). * Patients with decompensated Chronic liver disease. * Patients with uncontrolled hypertension. * Patients with blood pressure (BP) \> 110/70. * Patients already on the same medication (Sodium Glucose Co-Transporter 2 Inhibitors). * Patients with a history of recurrent or recent urinary tract infection (UTI). * Patients with glycated hemoglobin (HbA1c) ≤10. * Adult polycystic kidney disease. * All patients on immunosuppressive medications.

Design outcomes

Primary

Measure	Time frame	Description
Change in the estimated glomerular filtration rate	6 months post-procedure	Change in the estimated glomerular filtration rate (eGFR) was recorded.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026